New Nature Genetics paper from Tekpli's group: Why do some breast cancers respond to hormone therapy while others do not?

In a study published on 4 November in Nature Genetics, Ilayda Altinönder and Villads Winton from Xavier Tekpli’s group, together with Jürgen Geisler, Senior Consultant in Medical Oncology at Ahus, and their co-authors identified biological differences between breast tumors that respond well to aromatase inhibitors and those that do not.
Through longitudinal single-cell analyses of breast tumors, the authors found that tumors responding well to treatment were strongly associated with estrogen signaling, the pathway targeted by aromatase inhibitors.
Sensitivity to treatment was associated with a more active anti-tumor immune environment, including T cells and B cells that expanded and remained active during treatment.




